Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort


Por: Montoliu, A, Miro, JM, Domingo, P, Riera, M, Curran, A, Homar, F, Ambrosioni, J, Abdulghani, N, Force, L, Peraire, J, Vilaro, J, Masabeu, A, Orti, AJ, Dalmau, D, Casabona, J, Reyes, J, Bruguera, A, Muntada, E, Podzamczer, D, Llibre, JM, Navarro, G, Cortes, C, Falco, V, Mallolas, J, Manzardo, C, Imaz, A, Tiraboschi, J, Burgos, J, Mateo, MG, Gutierrez, MM, Murillas, J, Segura, F, Garcia-Gasalla, M, Puig, T, Vidal, F, Leon, E, Jaen, A, Almuedo, A, De Lazzari, E, Giralt, D, Martin, M, Gargoulas, F, Vanrell, T, Rubia, JC, Vila, J, Ferres, M, Morell, B, Tamayo, M, Laguno, M, Martinez, M, Blanco, JL, Garcia-Alcaide, F, Rojas, J, Martinez, E, Jou, A, Clotet, B, Saumoy, M, Silva, A, Prieto, P, Ribera, JNIE, Gurgui, M, Campins, AA, Fanjul, FJ, Leyes, M, Penaranda, M, Martin, L, Vilchez, H, Calzado, S, Cervantes, M, Amengual, MJ, Navarro, M, Payeras, T, Cifuentes, C, Comella, T, Vargas, M, Vilades, C, Barrufet, P, Chivite, I, Chamarro, E, Escrig, C, Cairo, M, Martinez-Lacasa, X, Font, R, Deig, E, Meyer, S, Hernandez, J

Publicada: 1 mar 2019
Resumen:
Objectives The aim of the study was to assess the rates of discontinuation of integrase inhibitor regimens because of any neuropsychiatric adverse event (NPAE) and the factors associated with discontinuation. Methods A population-based, prospective, multicentre cohort study was carried out. Treatment-naive subjects starting therapy with a regimen containing integrase inhibitors, or those switching to such a regimen, with plasma HIV-1 RNA < 50 HIV-1 RNA copies/mL in 14 hospitals in Catalonia or the Balearic Islands (Spain) were included in the study. Every discontinuation because of adverse events (AEs) was double-checked directly with treating physicians. Multivariable Cox models identified factors correlated with discontinuation. Results A total of 4165 subjects (37% treatment-naive) started regimens containing dolutegravir (n = 1650; 91% with abacavir), raltegravir (n = 930) or elvitegravir/cobicistat (n = 1585). There were no significant differences among regimens in the rate of discontinuation because of any AE. Rates of discontinuation because of NPAEs were low but higher for dolutegravir/abacavir/lamivudine [2.1%; 2.9 (95% confidence interval (CI) 2.0, 4.2) discontinuations/100 patients/year] versus elvitegravir/cobicistat (0.5%; 0.8 (95% CI 0.3, 1.5) discontinuations/100 patients/year], with significant differences among centres for dolutegravir/abacavir/lamivudine and NPAEs (P = 0.003). We identified an association of female gender and lower CD4 count with increased risk of discontinuation because of any AE [Incidence ratio (IR) 2.3 (95% CI 1.4, 4.0) and 1.8 (95% CI 1.1, 2.8), respectively]. Female gender, age > 60 years and abacavir use were not associated with NPAE discontinuations. NPAEs were commonly grade 1-2, and had been present before and improved after drug withdrawal. Conclusions In this large prospective cohort study, patients receiving dolutegravir, raltegravir or elvitegravir/cobicistat did not show significant differences in the rate of discontinuation because of any toxicity. The rate of discontinuations because of NPAEs was low, but was significantly higher for dolutegravir than for elvitegravir/cobicistat, with significant differences among centres, suggesting that greater predisposition to believe that a given adverse event is caused by a given drug of some treating physicians might play a role in the discordance seen between cohorts.

Filiaciones:
Montoliu, A:
 CEEISCAT, CIBERESP, Stat & Epidemiol, Badalona, Spain

 CEEISCAT, Badalona, Spain

Miro, JM:
 Univ Barcelona, IDIBAPS, Hosp Clin, Barcelona, Spain

Domingo, P:
 Hosp Santa Creu & Sant Pau, Infect Dis, Barcelona, Spain

 Hosp Santa Creu & Sant Pau, Barcelona, Spain

Riera, M:
 Hosp Son Espases, Palma De Mallorca, Spain

 Hosp Son Espases Mallorca, Palma De Mallorca, Spain

Curran, A:
 Hosp Univ Vall dHebron, Infect Dis, Barcelona, Spain

 Hosp Univ Vall dHebron, Barcelona, Spain

Homar, F:
 Hosp Son Llatzer, Palma De Mallorca, Spain

Ambrosioni, J:
 Univ Barcelona, IDIBAPS, Hosp Clin, Barcelona, Spain

Abdulghani, N:
 Hosp Santa Maria, Lleida, Spain

Force, L:
 Hosp Mataro Consorci Sanitari Maresme, Internal Med, Mataro, Spain

 Hosp Mataro Consorci Sanitari Maresme, Mataro, Spain

Peraire, J:
 Hosp Joan 23, Internal Med, Tarragona, Spain

 Hosp Joan 23, Tarragona, Spain

Vilaro, J:
 Hosp Gen Vic, Vic, Spain

Masabeu, A:
 Hosp Palamos, Palamos, Spain

Orti, AJ:
 Hosp Verge Cinta, Tortosa, Spain

 Hosp Verge Cinta Tortosa, Tortosa, Spain

Dalmau, D:
 Hosp Univ Mutua Terrassa, Terrassa, Spain

Casabona, J:
 CEEISCAT, CIBERESP, Stat & Epidemiol, Badalona, Spain

 CEEISCAT, CIBERESP, Badalona, Spain

Reyes, J:
 CEEISCAT, Badalona, Spain

Bruguera, A:
 CEEISCAT, Badalona, Spain

Muntada, E:
 CEEISCAT, Badalona, Spain

Podzamczer, D:
 Hosp Univ Bellvitge, IDIBELL, Barcelona, Spain

Llibre, JM:
 Univ Hosp Germans Trias & Pujol, Infect Dis & Fight AIDS Fdn, Badalona, Spain

 Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Fdn Lluita Sida, Barcelona, Spain

Navarro, G:
 Univ Autonoma Barcelona, Corp Sanitaria & Univ Parc Tauli, Barcelona, Spain

Cortes, C:
 Consorci Sanitari Integral, Barcelona, Spain

Falco, V:
 Hosp Univ Vall dHebron, Barcelona, Spain

Mallolas, J:
 Univ Barcelona, IDIBAPS, Hosp Clin, Barcelona, Spain

Manzardo, C:
 Univ Barcelona, IDIBAPS, Hosp Clin, Barcelona, Spain

Imaz, A:
 Hosp Univ Bellvitge, IDIBELL, Barcelona, Spain

Tiraboschi, J:
 Hosp Univ Bellvitge, IDIBELL, Infect Dis, Barcelona, Spain

 Hosp Univ Bellvitge, IDIBELL, Barcelona, Spain

Burgos, J:
 Hosp Univ Vall dHebron, Barcelona, Spain

Mateo, MG:
 Hosp Santa Creu & Sant Pau, Barcelona, Spain

Gutierrez, MM:
 Hosp Santa Creu & Sant Pau, Barcelona, Spain

Murillas, J:
 Hosp Son Espases Mallorca, Palma De Mallorca, Spain

Segura, F:
 Univ Autonoma Barcelona, Corp Sanitaria & Univ Parc Tauli, Barcelona, Spain

Garcia-Gasalla, M:
 Hosp Son Llatzer, Palma De Mallorca, Spain

Puig, T:
 Hosp Santa Maria, Lleida, Spain

Vidal, F:
 Hosp Joan 23, Tarragona, Spain

Leon, E:
 Consorci Sanitari Integral, Barcelona, Spain

Jaen, A:
 Hosp Univ Mutua Terrassa, Terrassa, Spain

Almuedo, A:
 Hosp Gen Granollers, Granollers, Spain

De Lazzari, E:
 Univ Barcelona, IDIBAPS, Hosp Clin, Barcelona, Spain

Giralt, D:
 Hosp Univ Bellvitge, IDIBELL, Barcelona, Spain

Martin, M:
 Hosp Univ Vall dHebron, Barcelona, Spain

Gargoulas, F:
 Hosp Son Espases, Palma De Mallorca, Spain

 Hosp Son Llatzer, Palma De Mallorca, Spain

Vanrell, T:
 Hosp Son Espases, Palma De Mallorca, Spain

 Hosp Son Llatzer, Palma De Mallorca, Spain

Rubia, JC:
 Consorci Sanitari Integral, Barcelona, Spain

Vila, J:
 Serv Salut Integrats Baix Emporda, Palamos, Spain

Ferres, M:
 Hosp Univ Mutua Terrassa, Terrassa, Spain

Morell, B:
 Hosp Santa Maria, Lleida, Spain

Tamayo, M:
 Hosp Gen Granollers, Granollers, Spain

Laguno, M:
 Univ Barcelona, IDIBAPS, Hosp Clin, Barcelona, Spain

Martinez, M:
 Univ Barcelona, IDIBAPS, Hosp Clin, Barcelona, Spain

Blanco, JL:
 Univ Barcelona, IDIBAPS, Hosp Clin, Barcelona, Spain

Garcia-Alcaide, F:
 Univ Barcelona, IDIBAPS, Hosp Clin, Barcelona, Spain

Rojas, J:
 Univ Barcelona, IDIBAPS, Hosp Clin, Barcelona, Spain

Martinez, E:
 Univ Barcelona, IDIBAPS, Hosp Clin, Barcelona, Spain

Jou, A:
 Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Fdn Irsicaixa, Fdn Lluita Sida, Barcelona, Spain

Clotet, B:
 Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Fdn Irsicaixa, Fdn Lluita Sida, Barcelona, Spain

Saumoy, M:
 Hosp Univ Bellvitge, IDIBELL, Barcelona, Spain

Silva, A:
 Hosp Univ Bellvitge, IDIBELL, Barcelona, Spain

Prieto, P:
 Hosp Univ Bellvitge, IDIBELL, Barcelona, Spain

Ribera, JNIE:
 Hosp Univ Vall dHebron, Barcelona, Spain

Gurgui, M:
 Hosp Santa Creu & Sant Pau, Barcelona, Spain

Campins, AA:
 Hosp Son Espases Mallorca, Palma De Mallorca, Spain

Fanjul, FJ:
 Hosp Son Espases Mallorca, Palma De Mallorca, Spain

Leyes, M:
 Hosp Son Espases Mallorca, Palma De Mallorca, Spain

Penaranda, M:
 Hosp Son Espases Mallorca, Palma De Mallorca, Spain

Martin, L:
 Hosp Son Espases Mallorca, Palma De Mallorca, Spain

Vilchez, H:
 Hosp Son Espases Mallorca, Palma De Mallorca, Spain

Calzado, S:
 Univ Autonoma Barcelona, Corp Sanitaria & Univ Parc Tauli, Barcelona, Spain

Cervantes, M:
 Univ Autonoma Barcelona, Corp Sanitaria & Univ Parc Tauli, Barcelona, Spain

Amengual, MJ:
 Univ Autonoma Barcelona, Corp Sanitaria & Univ Parc Tauli, Barcelona, Spain

Navarro, M:
 Univ Autonoma Barcelona, Corp Sanitaria & Univ Parc Tauli, Barcelona, Spain

Payeras, T:
 Hosp Son Llatzer, Palma De Mallorca, Spain

Cifuentes, C:
 Hosp Son Llatzer, Palma De Mallorca, Spain

Comella, T:
 Hosp Santa Maria, Lleida, Spain

Vargas, M:
 Hosp Joan 23, Tarragona, Spain

Vilades, C:
 Hosp Joan 23, Tarragona, Spain

Barrufet, P:
 Hosp Mataro Consorci Sanitari Maresme, Mataro, Spain

Chivite, I:
 Consorci Sanitari Integral, Barcelona, Spain

Chamarro, E:
 Hosp Verge Cinta Tortosa, Tortosa, Spain

Escrig, C:
 Hosp Verge Cinta Tortosa, Tortosa, Spain

Cairo, M:
 Hosp Univ Mutua Terrassa, Terrassa, Spain

Martinez-Lacasa, X:
 Hosp Univ Mutua Terrassa, Terrassa, Spain

Font, R:
 Hosp Univ Mutua Terrassa, Terrassa, Spain

Deig, E:
 Hosp Gen Granollers, Granollers, Spain

Meyer, S:
 Comite 1er Desembre, Barcelona, Spain

Hernandez, J:
 Comite 1er Desembre, Barcelona, Spain
ISSN: 14642662





HIV MEDICINE
Editorial
WILEY, 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Reino Unido
Tipo de documento: Article
Volumen: 20 Número: 3
Páginas: 237-247
WOS Id: 000458338700008
ID de PubMed: 30688007

MÉTRICAS